TY - JOUR
T1 - Akut eksacerbation af fibrotiske interstitielle lungesygdomme
T2 - Acute exacerbation of fibrotic interstitial lung diseases
AU - Hoyer, Nils
AU - Bendstrup, Elizabeth
AU - Davidsen, Jesper Rømhild
AU - Lund, Thomas Kromann
AU - Shaker, Saher Burhan
PY - 2023/8/14
Y1 - 2023/8/14
N2 - Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and other fibrotic interstitial lung diseases (AE-ILD) is defined by significant acute respiratory worsening and new widespread alveolar damage. This review summarises the current knowledge of diagnosis and treatment of these events. The diagnosis of AE-IPF and AE-ILD is based on typical HRCT findings of new and bilateral ground glass opacification and/or consolidation, and exclusion of fluid overload or cardiac failure. Treatment relies, despite low quality of evidence, on glucocorticoid in addition to supportive and palliative treatment. Despite treatment, the prognosis is poor, with a median survival of 2-4 months.
AB - Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and other fibrotic interstitial lung diseases (AE-ILD) is defined by significant acute respiratory worsening and new widespread alveolar damage. This review summarises the current knowledge of diagnosis and treatment of these events. The diagnosis of AE-IPF and AE-ILD is based on typical HRCT findings of new and bilateral ground glass opacification and/or consolidation, and exclusion of fluid overload or cardiac failure. Treatment relies, despite low quality of evidence, on glucocorticoid in addition to supportive and palliative treatment. Despite treatment, the prognosis is poor, with a median survival of 2-4 months.
KW - Glucocorticoids/therapeutic use
KW - Heart Failure
KW - Humans
KW - Idiopathic Pulmonary Fibrosis/diagnostic imaging
KW - Lung Diseases, Interstitial/diagnostic imaging
KW - Palliative Care
M3 - Tidsskriftartikel
C2 - 37615152
SN - 0041-5782
JO - Ugeskrift for Læger
JF - Ugeskrift for Læger
M1 - V04230261
ER -